Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.
Ars Pharmaceuticals is expanding its $199 neffy retail access program while awaiting a crucial decision from CVS Caremark, aiming to boost affordability...
LENZ Therapeutics delivered Q1 2026 results consistent with expectations, achieving $1.9 million in net revenue and approximately 25,000 prescriptions. The company also...
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...
Recursion Pharmaceuticals projects its operational runway into early 2028 while committing to keep 2026 cash operating expenses under $390 million, driven by...
Quantum BioPharma Ltd. has engaged Senergy Communications Capital Inc. and King Tide Media LLC for a one-month contract to bolster investor awareness...
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.